Frontiers in Nephrology (Jul 2024)

A case report of dipeptidyl peptidase 4 inhibitor-related kidney disease combined with renal cancer

  • Shigekazu Kurihara,
  • Naoki Sawa,
  • Keiichi Sumida,
  • Daisuke Ikuma,
  • Yuki Oba,
  • Hiroki Mizuno,
  • Akinari Sekine,
  • Masayuki Yamanouchi,
  • Eiko Hasegawa,
  • Tatsuya Suwabe,
  • Shinji Urakami,
  • Kei Kono,
  • Keiichi Kinowaki,
  • Kenichi Ohashi,
  • Kenichi Ohashi,
  • Yutaka Yamaguchi,
  • Yoshifumi Ubara

DOI
https://doi.org/10.3389/fneph.2024.1409098
Journal volume & issue
Vol. 4

Abstract

Read online

A kidney biopsy was performed in a 64-year-old woman with type 2 diabetes mellitus and less than 1 g of proteinuria who rapidly progressed to end-stage renal failure after approximately 2 years of treatment with two dipeptidyl peptidase 4 (DPP-4) inhibitors for type 2 diabetes mellitus. The biopsy revealed not only a coincidental diagnosis of renal cell carcinoma, which was not evident on pre-biopsy computed tomography, but also severe thrombotic microangiopathy (TMA)-like glomerular endothelial cell damage in the noncancerous areas. These results suggest that DPP4 inhibitors may have been involved in two kidney diseases.

Keywords